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Background: In patients infected with human immunodeficiency virus 1 (HIV-1) neuropathic symptoms may
develop within weeks of starting combination antiretroviral therapy (cART). This timing coincides with the
occurrence of immune reconstitution inflammatory syndrome. Our objective was to investigate the longitudinal
association of plasma cytokine and soluble receptor concentrations with incident neuropathic symptoms within 12
weeks of starting programme-based cART in a nested case-control study.
Methods: One hundred and twenty adults without neuropathic symptoms and about to initiate cART were
followed longitudinally for 24 weeks after cART initiation. Subjects were examined for peripheral neuropathy at
baseline (pre-cART) and 2-, 4-, 12- and 24 weeks thereafter. Individuals developing neuropathic symptoms within 12
weeks of starting cART were matched in a nested case-control design with those remaining symptom-free for at
least 24 weeks. Plasma was collected at each visit. Cytokines and soluble receptors were quantified using multiplex
immunometric assays.
Results: Incident neuropathic symptoms occurred in 32 (27%) individuals within 12 weeks of starting cART for the
first time. Cytokine concentrations increased at 2 weeks, irrespective of symptom-status, returning to baseline
concentrations at 12 weeks. Compared to the control group, the symptomatic group had higher baseline levels of
interleukin-1 receptor (IL-1R)-antagonist. The symptomatic group also showed greater increases in soluble
interleukin-2 receptor-alpha and tumour necrosis factor (TNF) receptor-II levels at week 2 and soluble interleukin-6
receptor levels at week 12. Ratios of pro-inflammatory- vs anti-inflammatory cytokines were higher for
TNF-alpha/IL-4 (p = 0.022) and interferon-gamma/IL-10 (p = 0.044) in those developing symptoms. After 24 weeks
of cART, the symptomatic group showed higher CD4+ counts (p = 0.002).
Conclusions: The initiation of cART in previously treatment naïve individuals was associated with a cytokine ‘burst’
between 2- and 4 weeks compared with pre-cART levels. Individuals developing neuropathic symptoms within 12
weeks of starting cART showed evidence of altered cytokine concentrations even prior to initiating cART, most
notably higher circulating IL-1R-antagonist levels, and altered ratios of “pain-associated” cytokine and soluble
receptors shortly after cART initiation.
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Distal sensory polyneuropathy (DSP) is the most prevalent
neuropathy in individuals infected with human immuno-
deficiency virus 1 (HIV-1) and occurs in up to 57% [1,2].
HIV-1-associated DSP includes two clinically identical
neuropathies arising either as a consequence of HIV-1 in-
fection (HIV-DSP) or a treatment-induced toxicity from
combination antiretroviral therapy (cART) predominantly
as a result from exposure to the di-deoxynucleoside re-
verse transcriptase inhibitors (dNRTI’s). HIV-1 associated
DSP is characterized by a high frequency of positive sen-
sory neuropathic symptoms such as pain and paresthesiae
[1]. The development of incident neuropathic symptoms
peaks within 12 weeks of starting cART [3].
The pathogenesis of HIV-1-associated DSP remains ob-
scure, although likely many factors are at play [4]. For
HIV-DSP, the most widely accepted pathogenic mechan-
ism involves neuronal damage secondary to immune acti-
vation with release of cytokines and oxygen-radicals [5].
Mitochondrial dysfunction is associated with exposure to
nucleoside reverse-transcriptase inhibitor (NRTI) therapy
[6] and believed to contribute to the pathogenesis of
sensory neuropathy after cART initiation [7]. Despite
well-documented in vitro studies on mitochondrial DNA
polymerase-γ inhibition by NRTIs, studies have not
consistently demonstrated a correlation between mito-
chondrial dysfunction and the presence of NRTI-related
adverse effects [8]. Not all individuals treated with NRTIs
develop adverse effects related to mitochondrial toxicity.
Host factors such as differences in the intracellular
phosphorylation of NRTIs, drug–drug or drug–nutrient
interactions, and nadir CD4+ counts have been sug-
gested to influence susceptibility towards mitochondrial
dysfunction [9-12].
Substantial evidence implicates inflammation and cy-
tokines in the development of neuropathic pain. In ani-
mal models, peripheral nerve injury leads to rapid and
sustained changes in cytokine expression [13,14]. The
intraneural application of pro-inflammatory cytokines
induces pain-associated behavioural signs [15] which di-
minish when treated with anti-inflammatory cytokines
[16]. In HIV-1-negative individuals with painful- com-
pared to painless neuropathies, higher blood mRNA levels
of tumour necrosis factor-alpha (TNFα) and interleukin
(IL)-2 have been reported [17].
Few studies have assessed the role of cytokines in HIV-
1-associated DSP. In a cross-sectional cohort, largely on
cART, several markers of immune activation in the plasma
and cerebrospinal fluid (CSF) were studied; only CSF
macrophage colony-stimulating factor levels predicted
time to developing symptomatic DSP [18]. A study of
cytokine gene polymorphisms in individuals with DSP
after cART initiation, with or without symptoms, showed
an association with the TNFA-locus [19]. Increased TNFαand reduced IL-4 mRNA levels were also found in periph-
eral nerve tissue from AIDS patients with DSP [20]. Indi-
viduals with HIV-1-associated DSP compared to those
without were found to have persistently higher levels of
chemokine ligand 5 (CCL5) during the first 48 weeks after
cART [21].
Upon starting cART, immune reconstitution is accom-
panied by a rise in CD4+ count and partial restoration of
pathogen-specific immunity [22]. However, 8-43% of pa-
tients will experience pathological inflammatory responses
that may cause clinical deterioration, termed immune
reconstitution inflammatory syndrome (IRIS) [23,24].
Typically, IRIS occurs during the first 12 weeks of cART
initiation [25], and in the setting of HIV-1 and tubercu-
losis co-infection, has been shown to be associated with
increased circulating pro-inflammatory cytokines TNFα,
IL-6, and interferon-gamma (IFN-γ) [26].
As IRIS manifests within a similar period to the devel-
opment of incident neuropathic symptoms after cART
initiation we hypothesized that an exaggerated cytokine
response or immune reconstitution after cART initiation
contributes to the immunopathogenesis of neuropathic
symptoms [3]. We investigated the association between
neuropathic symptoms and the concentrations of markers
previously shown to be associated with painful neuropa-
thies and/or immune reconstitution, within 12 weeks after
cART initiation. These markers included high-sensitivity
C-reactive protein (hs-CRP), CD4+ count as well as spe-
cific cytokines TNFα, IL-2, IL-4, IL-6 and their soluble
receptors.
Methods
The University of Cape Town Research Ethics Commit-
tee approved the study (REC REF 221/2008). All subjects
provided written informed consent.
Study site, subjects and study design
HIV-1-infected individuals who were treatment naïve, but
scheduled to start cART within the next seven days were re-
cruited from Crossroads Community Health Centre (Cape
Town, South Africa) between May 2009 and December
2010. Individuals were eligible if ≥18 years and met criteria
for cART initiation in the government-sponsored HIV treat-
ment programme, i.e. a CD4+ count ≤350 cells/mm3.
Individuals with pre-existing symptoms at the baseline
visit, were excluded from further analysis. In addition,
those with previous exposure to cART, diabetes mellitus,
active opportunistic infection, additional systemic illness
or inflammatory conditions, current infection with tuber-
culosis, severe diarrhoea, co-morbid neurological disease
that may confound DSP, exposure to glucocorticoids within
preceding six months, or pregnancy, were excluded.
Clinical assessments were performed on all eligible
participants at baseline (pre-cART) and 2-, 4-, 12-, and
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tained at each visit. Peripheral nervous system examin-
ation was performed by one of two trained clinicians
using the Brief Peripheral Neuropathy Screen and a
modified version of Total Neuropathy Score (TNSr) as
previously described [1]. These tools include assessments
of neuropathic symptoms of pain, numbness, and par-
aesthesiae on a visual analogue scale (VAS)(0-10) as well
as neurological signs including pinprick and vibratory
sensation, reflexes, and strength assessments.
The symptomatic group comprised individuals develop-
ing neuropathic symptoms within 12 weeks of starting
cART. A nested case-control cohort was selected consisting
of 30 individuals who did not develop symptoms for 24
weeks after cART initiation (control group). The groups
were paired using risk factors previously reported such as
age (difference ≤3 years), gender, previous anti-tuberculous
treatment, baseline CD4+ count (difference ≤25 cells/mm3)
and dNRTI containing regimens [1,27,28].
Sampling and cytokine assays
Sampling was performed at baseline, 2-, 4- and 12 weeks
thereafter. Fasting venous blood was collected between
08h00-09h00 to reduce variability (diurnal variations or
food ingestion). Samples were immediately placed on ice
until centrifuged (<3 hours) and stored at -80°C.
Plasma concentrations of granulocyte-macrophage
colony-stimulating factor (GM-CSF), IFNγ, IL-1β, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13, and
TNFα were quantified using a multiplexed (Bio-Plex
platform) immunometric assay (MILLIPLEX xMAP High
Sensitivity Human Cytokine Panel, Millipore, Billerica,
MA, USA). Plasma cytokine receptor concentrations of
soluble IL (sIL)-1 receptor I (sIL-1RI), sIL-1 receptor II
(sIL-1RII), sIL-2 receptor-α (sIL-2Rα), sIL-4 receptor (sIL-
4R), sIL-6 receptor (sIL-6R), sTNF receptor I (sTNFRI),
and sTNF receptor II (sTNFRII) were quantified using
MILLIPLEX xMAP Human Soluble Cytokine Receptor
Panel. IL-l receptor antagonist (IL-1RA) was quantified by
using MILLIPLEX xMAP Human Cytokine/Chemokine
Immunoassay. Assays were carried out in compliance with
the kit manufacturer. Concentrations lower than the kit’s
limit of detection were extrapolated from a standard
curve. Each subject’s samples were prepared on the same
plate to minimize inter-plate variability.
High-sensitivity CRP was measured by a particle-
enhanced immunoturbidimetric assay (Roche Diagnos-
tics, Mannheim, Germany). CD4+ counts, week 24 viral
load, and white cell counts were obtained from chart
reviews.
Statistical analysis
Stata (version 12.0; Texas, USA) was used. Baseline charac-
teristics, cytokine, and soluble receptor concentrations weresummarized by proportions or median with interquartile
range (IQR). Normality was assessed numerically and log-
transformation was applied when necessary. Baseline differ-
ences between groups were assessed by Chi-square or
Fisher’s exact test and Student-t or Mann-Whitney U test,
as appropriate. Repeated measures analysis (random effects
model with cross-sectional time series regression) assessed
longitudinal patterns (over time and between groups). Time
since cART was used as the within-individual factor and
group (symptomatic vs symptom-free) as the between-
individual factor. To exclude the effect of random variation
and significant fluctuations within an individual’s cytokine
peak measurements over time, a Spearman rank correlation
analysis was performed. All p-values were two-sided at 5%
significance. P-values were not corrected for multiple com-




All baseline examinations were performed a median of
one day prior to cART initiation (IQR 1-5 days). One-
hundred and eighty-four eligible patients were screened
at baseline and 24 with neuropathic symptoms were
excluded. A further 40 subjects defaulted either due to
pregnancy, migration, withdrawal of consent or devel-
oped tuberculosis. For the nested sample, cases and con-
trols were selected from the prevalent cohort (n = 120)
without symptoms at the baseline visit and who were
followed for 24 weeks. Within the first 12 weeks of start-
ing cART, 32 (27%) of these individuals developed neuro-
pathic symptoms; two were excluded from further analysis
because of detectable viral loads at week 24 and the
remaining 30 comprised the symptomatic group.
Of the individuals who remained symptom-free for 24
weeks, 30 were selected as controls after matching them
with the symptomatic group for known risk factors such
that no differences were observed in baseline characteris-
tics (Table 1). The baseline characteristics of the matched
controls did not differ from the overall cohort without
neuropathic symptoms (n = 88; Table 1). Fasting glucose
(median = 4.7; normal 4.1-5.6 mmol/L) and triglycerides
levels (median = 0.8; normal 0.5-2.0 mmol/L) were normal
and similar between the symptomatic- and control groups
(p ≥ 0.53, results not shown) as well as alcohol consump-
tion (any alcohol in the preceding year, 31%; p = 0.83).
The median age of the nested case-control group was
33 years (range 20-47). More than half of the individuals
had been diagnosed with HIV-1 infection within a year
preceding the baseline visit; overall, there was no differ-
ence between the case- and control groups (p = 0.22).
The WHO HIV stage, baseline white cell count (median =
5.7 × 109/l), CD4+ count (median = 141/mm3) and hs-CRP
(median = 2.7 mg/L) were similar, as were weight and
Table 1 Baseline (pre-cART) clinical and laboratory characteristics by incident neuropathic symptom status
Nested case (neuropathic symptoms) vs control (symptom-free) sample
Variable Total cohort remaining
symptom-free N = 88
Neuropathic symptom
group N = 30
Control group N = 30 Total N = 60
Female sex, N (%) 62 (70) 22 (73) 22 (73) 44 (73)
Age*, years 31 (27 – 38) 32 (26 - 35) 34 (26 - 41) 33 (26 - 37)
Weight*, kg 63 (56- 72) 58.0 (52.5 - 68.5) 59.5 (54.0 - 64.0) 58.5 (53.0 - 68.0)
Height*, m 1.61 (1.56 - 1.69) 1.58 (1.55 - 1.64) 1.62 (1.57 - 1.65) 1.61 (1.55 - 1.64)
Body Mass Index*, kg/m2 23.3 (20.3 - 28.0) 22.7 (20.1 - 28.0) 22.6 (19.8 - 25.3) 22.6 (19.8 - 28.0)
dNRTI†, N (%) 68 (77) 24 (40) 22 (37) 46 (77)
D4T/3TC/NNRTI 68 (77) 24 (40) 22 (37) 46 (77)
AZT/3TC/NNRTI 5 (6) 2 (7) 3 (10) 5 (8)
TDF/3TC/NNRTI 15 (17) 4 (13) 5 (17) 9 (15)
Previous TB, N (%) 25 (28) 7 (23) 7 (23) 14 (23)
< 1 year ago 13 (15) 3 (10) 3 (10) 6 (10)
1 year ago 1 (1) 0 (0) 0 (0) 0 (0)
2 years ago 2 (2) 0 (0) 1 (3) 1 (2)
> 2 years ago 9 (10) 4 (13) 3 (10) 7 (12)
Years since HIV diagnosis* 1 (1-3.4) 1 (1-3.5) 2 (1-4) 1 (1-3.8)
WHO stage, N (%)
Stage 1 30 (34) 6 (20) 12 (40) 18 (30)
Stage 2 25 (28) 18 (60) 10 (33) 28 (47)
Stage 3 30 (34) 5 (17) 7 (23) 12 (20)
Stage 4 3 (3) 1 (3) 1 (3) 2 (3)
White cell count*, ×109/L 5.1 (4.0 - 6.6) 5.7 (3.9 - 6.4) 5.7 (4.4 - 7.9) 5.7 (4.3 - 7.1)
CD4 T-cell count*, cells/mm3 163 (125 - 193) 145 (109 - 181) 138 (110 - 194) 141 (110 - 189)
CD4 T-cell count, N (%)
< 100 cells/mm3 15 (17) 5 (17) 6 (20) 11 (18)
100 - 200 cells/mm3 56 (64) 19 (63) 20 (67) 39 (65)
> 200 cells/mm3 17 (19) 6 (20) 4 (13) 10 (17)
hs-CRP*, mg/L 2.6 (0.9 - 6.5) 2.6 (0.9 - 5.4) 2.9 (0.9 - 6.7) 2.7 (0.9 - 6.7)
The total cohort remaining symptom-free refers to individuals who were asymptomtic at baseline and remained free of neuropathic symptoms in the first 6
months of starting cART; the nested control group were extracted from this total cohort and paired (with the neuropathic symptom group) for previously
identified risk factors. The neuropathic symptom group refers to individuals developing symptoms within 12 weeks of starting cART.
Abbreviations: dNRTI dideoxy-nucleoside reverse-transcriptase inhibitor (d-drug), D4T stavudine, 3TC lamivudine, AZT zidovudine, TDF tenofovir, TB tuberculosis,
WHO World Health Organization, hs-CRP high-sensitivity C-reactive protein.
*Median (Interquartile range).
†dNRTI refers to d-drug containing combination antiretroviral therapy regimen commenced subsequent to baseline assessment. NNRTI refers to non-nucleoside
reverse transcriptase inhibitor and were either efavirenz or nevirapine.
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unavailable.
Characteristics of subjects developing neuropathic
symptoms
The peak incidence in symptoms was between weeks 4
and 12 (14%) (Table 2). Overall, estimated crude inci-
dence rate at 24 weeks was 30%. The most frequent
symptom was paraesthesiae (25/30), followed by numb-
ness (21/30) and pain (15/30). Numbness never oc-
curred as an isolated neuropathic symptom. At initialpresentation the median pain/paresthesiae severity by
VAS was 4 (IQR 1-6).
Eleven of 30 individuals developing incident symptoms
had distal neuropathic signs at baseline; six had hypoactive
ankle reflexes compared to the knees, four had reduced
pin sensibility and one reduced vibration perception. Inci-
dent symptoms were accompanied by new/worsening
neuropathic sign(s) in 15 (50%). By week 24 after cART
initiation, pain or paresthesiae had resolved in 17 (transi-
ent symptoms), whereas the remainder had persistent or
worsening symptoms.
Table 2 Incidence of neuropathic symptoms within 24
weeks after cART initiation
Interval (weeks) Incident SN r1 R1
0 – 2 6 0.06 0.06
2 – 4 10 0.10 0.15
4 – 12 16 0.14 0.27
12 – 24 4 0.04 0.30
r1 is calculated as the ratio of the number of individuals who developed
neuropathic symptoms to the number of patients at risk during the interval.
R1 is the cumulative rate of development of neuropathic symptoms by end of
the interval.
For further analysis, 2 individuals with incident neuropathic symptoms were
excluded due to detectable HIV-1 viral loads at week 24.
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Baseline pre-cART cytokine concentrations were similar
between the symptomatic and control groups (Figure 1
and Additional file 1: Table S1). Median concentrations
of IL-4, IL-12(p70) and IL-13 were below the minimum
detectable level at baseline (Additional file 1: Table S2).
The initiation of cART significantly affected both pro-
and anti-inflammatory cytokine concentrations, irrespect-
ive of the development of neuropathic symptoms. Almost
all the cytokines measured demonstrated significantly
higher concentrations at week 2 and week 4 returning to
baseline levels by week 12, and included IL-1β, IL-2, IL-4,
IL-5, IL-6, IL-7, IL-10, IL-12p(70), IL-13, IFNγ, GM-CSF
and TNFα (Figure 1 and Additional file 1: Table S1). The
exception was IL-8 with lower levels at week 12 compared
to baseline. Irrespective of symptom status, TNFα in-
creased from pre-cART levels, peaked between weeks 2
and 4, but then decreased at week 12 to a lower level than
at baseline (p = 0.008). At week 12, IL-6 levels remained
higher compared to that at baseline (p = 0.033). Cytokine
levels showed within-individual stability and predictability
by correlating significantly at two different time points for
11 cytokines, and at three time points for four of the 11
(Additional file 1: Table S3).
The pro-inflammatory T-helper (Th)-1 cytokines showed
the greatest increases from baseline concentrations; IL-12p
(70) (≈700-fold), IL-2 (≈300-fold) and IFNγ (≈200-fold).
TNFα concentrations increased 3-fold. Compared with
baseline, Th2 cytokine levels also responded to cART
initiation; at week 2, IL-13 increased 59-fold and IL-4 36-
fold. IL-5 and IL-10 increased by comparatively modest
amounts (4- to 5-fold). The hs-CRP levels increased in
both groups compared to pre-cART levels, and peaked at
week 2 (p = 0.001) without significant differences by symp-
tom status (Table 3).
Plasma cytokines in the symptomatic group compared to
the control group
Despite the general increase in cytokine concentrations,
there was a tendency for lower peak concentrations in
the symptomatic group compared to the control group.However, individuals in the symptomatic group with per-
sistent symptoms throughout the 24-week period com-
pared to those developing transient symptoms, showed a
significantly greater IL-6 peak at week 2 (p = 0.023)
(Additional file 1: Table S4). Symptom severity, catego-
rized by a VAS cut-off of 4/10, did not associate with
cytokine concentrations at any sampling point (Additional
file 1: Table S4). After 24 weeks of cART, the symptomatic
group showed greater CD4+ count reconstitution com-
pared with those remaining symptom-free (298 cells/mm3;
IQR 210-457 vs 260 cells/mm3; IQR 179-351, p = 0.002)
(Table 3).
Stratifying the overall cohort by dNRTI exposure or
CD4+ counts >100 cells/mm3 did not show an associ-
ation with cytokine concentrations at any sampling point
(Results not shown).
Soluble cytokine receptors
The half-life of soluble cytokine receptors is longer than
that of cytokines. Therefore, soluble cytokine receptors
may be more informative of chronic inflammation [29].
In the symptomatic group compared to the control group,
the baseline median IL-1RA concentrations were signifi-
cantly higher (10.2 vs 1.9 pg/mL, p = 0.03), and remained
higher throughout the study period (Table 4). However, 26
of 60 individuals (6 symptomatic and 20 symptom-free)
had baseline IL-1RA concentrations lower than the de-
tectable level.
After starting cART, concentrations of sTNFRII, sIL-
2Rα and sIL-6R all declined significantly in both groups
from baseline levels over the 12-week study period, al-
beit at different sampling points (Table 4); sTNFRII was
significantly lower at 2 weeks, sIL-2Rα at 4 weeks, and
sIL-6R at 12 weeks. However, a repeated measures analysis
showed that concentrations of sIL-2Rα and sTNFRII two
weeks after cART initiation, were significantly higher in
the group developing neuropathic symptoms compared to
the control group (sTNFRII, p = 0.031; sIL-2Rα, p = 0.034)
(Table 4). Soluble receptors sIL-1RI, sIL-1RII and sTNFRI
remained relatively stable throughout.
Pro-inflammatory/anti-inflammatory cytokine ratios and
cytokine/soluble receptor ratios
The balance of pro- and anti-inflammatory cytokines may
be as important as individual cytokine concentrations.
Therefore, we assessed ratios of pro- and anti-inflammatory
cytokines and their soluble receptors as markers of a dys-
regulated immune response [29-32]. At week 2, the symp-
tomatic group compared with the control group showed
lower ratios of cytokines to soluble cytokine receptors: IL-
1β/sIL-1RI (p = 0.004), IL-1β/IL-1RA (p = 0.006) and IL-2/
sIL-2Rα (p = 0.014) (Figure 2). At the same time point, the
“pain-associated” cytokines of a priori interest showed
higher ratios in the symptomatic group for TNFα/IL-4 (p =
Figure 1 Longitudinal evaluation of candidate cytokine concentrations categorized by incident neuropathic symptom status. Incident
neuropathic symptoms developed within 12 weeks of starting cART. The control group refers to the symptom-free nested control group paired
for previously identified risk factors. *refers to within-group differences from baseline, p < 0.05. # refers to between-group differences from
baseline levels, p < 0.05. Horizontal bars indicate median values with interquartile ranges. Baseline refers to pre-cART levels. Abbreviations: IL,
interleukin; TNFα, tumour necrosis factor-α.
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Table 3 CD4+ count and high-sensitivity CRP pre-cART and longitudinally over 12 weeks, categorized by neuropathic
symptom status
Variable Time point Time effect Group effect
Median (IQR), pg/ml Neuropathic symptom
group Median (IQR)
Control group Median (IQR)
CD4+ count, cells/mm3 Baseline 141 (110; 189) 145 (109; 181) 138 (110; 194)
Week 24 272 (204; 368) 298 (210; 457) 260 (179; 351)
hs-CRP, mg/L Baseline 2.70 (0.90; 6.70) 2.90 (0.90; 6.70) 2.60 (0.90; 5.40)
Week 2 6.70 (2.10; 18.50) 8.40 (3.40; 17.00) 5.30 (1.80; 19.30)
Week 4 6.50 (3.30; 26.50) 8.40 (3.50; 30.60) 4.20 (3.30; 15.00)
Week 12 3.95 (1.50; 7.20) 3.80 (1.50; 8.30) 4.20 (1.00; 6.70)
Incident neuropathic symptoms developed within 12 weeks of starting cART.
The control group refers to the symptom-free nested control group paired for previously identified risk factors.
Time effect: Bold numbers denote values different from baseline, p < 0.05.
Group effect: Bold numbers denote values different between groups compared to baseline, p < 0.05.
Abbreviations: IQR interquartile range, hs-CRP high-sensitivity C-reactive protein.
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(p = 0.061). At week 12 the symptomatic group still had a
higher IFNγ/IL-10 ratio (p = 0.044) (Figure 2).
Discussion
The development of incident neuropathic symptoms
within 12 weeks of starting cART developed in 27% of
our community-based cohort. The peak period of devel-
oping neuropathic symptoms was between 2 and 12
weeks, with 10% occurring in 2-4 weeks and 14% between
4-12 weeks. Few prior studies have evaluated neuropathy
status at 12 weeks, all with incomplete data [3,33]; at 24
weeks, our crude incidence rate of 30% is similar to that
of a Ugandan cohort reporting 38% with incident neuro-
pathic symptoms [33].
Comparison of plasma cytokines in the symptomatic and
control groups showed significant differences in only two
cytokines at 2 weeks (IL-1β and IL-13, Additional file 1:
Table S1). However, baseline IL-1RA were 5-times higher
in the symptomatic group preceding the clinical onset of
symptoms and the initiation of cART. IL-1RA has features
of an acute phase protein [29] suggesting that in individ-
uals susceptible to developing neuropathic symptoms,
there may be a higher set-point of sub-clinical inflamma-
tion pre-cART. Two weeks after starting cART, the sIL-
2Rα and sTNFRII also showed higher peak concentrations
in the symptomatic group compared with the controls
remaining symptom-free. Furthermore, at 24 weeks the
symptomatic group showed greater reconstitution of the
CD4+ cell count.
Not all subjects developing symptoms remained symp-
tomatic by 24 weeks. Those with persistent symptoms at
24 weeks showed higher circulating IL-6 levels when com-
pared to those with transient neuropathic symptoms. Im-
portantly, two individuals with detectable viral loads at 24
weeks were excluded to minimize the confounding effect
of uncontrolled HIV-1 infection. Taken together theseresults suggest that patients developing symptoms within
the first 12 weeks after starting cART experience en-
hanced sub-clinical inflammation and immune reconstitu-
tion in the systemic compartment compared to those
remaining symptom-free.
Previously, higher levels of systemic TNFα- and IL-2-
mRNA were reported in HIV-1-negative painful neurop-
athies when compared with painless neuropathies [17].
Although in our study plasma IL-2 and TNFα concen-
trations did not mirror the soluble receptor levels or
segregate by symptom status, the systemic cytokine con-
centrations of both were substantially lower than the
concentrations of their respective soluble receptors (sIL-
2Rα, sTNFRI and sTNFRII). A possible explanation is
that IL-2 and TNFα, secreted by Th1 cells, act locally in
an autocrine or a paracrine manner and are neutralized
systemically by their soluble receptors as an immune regu-
latory mechanism [34]. Furthermore, the longer plasma
half-life of these soluble receptors and their rapid bio-
logical inactivation of systemic cytokines suggest that the
elevated levels detected in some soluble receptors in the
symptomatic group may indicate a relatively higher level
of inflammation [35,36].
In order to further explore markers of immune dysreg-
ulation we assessed ratios of key cytokines previously
implicated in neuropathic pain [17,20]. The ratios of
TNFα/IL-4 and IL-6/IL-4 were significantly higher at 2
weeks and IFNγ/IL-10 at 12 weeks in the symptomatic
group compared to the control group. These findings
suggest that in those developing symptoms, there is an
imbalance between pro- and anti-inflammatory cytokines
in which Th1 subsets and their cytokine products (IL-6,
IFNγ and TNFα), dominate over immunoregulatory Th2
subsets and their cytokines ( IL-4 and IL-10).
A novel observation was the transient but significant
burst in both pro- and anti-inflammatory plasma cyto-
kine concentrations, as well as hs-CRP levels, within 2-4
Table 4 Soluble receptor and IL-1RA concentrations pre-cART and longitudinally over 12 weeks, categorized by neuro-
pathic symptom status
Cytokine Time point Time effect Group effect
Median (IQR) (pg/mL) Neuropathic symptom-group Median
(IQR) (pg/mL)
Control group Median (IQR) (pg/mL)
sIL-1RI Baseline 29.6 (23.1; 41.0) 33.3 (23.2; 43.1) 25.5 (23.0; 34.3)
Week 2 34.0 (26.6; 45.6) 36.9 (29.0; 48.3) 33.6 (25.2; 39.5)
Week 4 37.6 (28.2; 45.6) 37.5 (27.4; 46.1) 38.7 (28.9; 42.9)
Week 12 28.2 (23.4; 38.9) 34.5 (26.3; 44.2) 25.2 (22.5; 35.0)
sIL-1RII Baseline 4572 (1904.5; 6339.5) 4160.6 (1593.2; 5550.0) 4922.8 (2017.9; 6489.5)
Week 2 4885.7 (2144.1; 7056.3) 4744.4 (2144.1; 6174.4) 4905.8 (2027.0; 8988.9)
Week 4 5116.7 (2453.1; 7658.8) 5115.7 (2453.1; 7443.9) 5751.6 (2674.1; 8659.4)
Week 12 5806.5 (2726.7; 8628.2) 5604.6 (2622.7; 8295.6) 6152.1 (2845.9; 8651.8)
sIL-2rα Baseline 1102.3 (728.1; 2021.5) 1068.2 (699.0; 2005.3) 1210.3 (757.1; 2383.1)
Week 2 1049.2 (595.1; 1781.7) 1188.4 (638.5; 1831.3) 866.1 (472.3; 1589.2)
Week 4 881.2 (580.8; 1763.4) 745.5 (595.0; 1230.0) 1032.1 (558.8; 1763.4)
Week 12 733.3 (434.6; 1073.1) 647.1 (432.9; 869.5) 823.8 (610.9; 1264.5)
sIL-6R Baseline 9379.3 (6441.9; 12912.4) 9379.3 (6386.6; 12726.3) 9545.9 (6518.4; 15032.9)
Week 2 9480.6 (7325.3; 14352.6) 10038.4 (7421.2; 14014.9) 9183.6 (6446.9; 15126.8)
Week 4 11538.0 (8288.9; 14148.6) 11248.9 (7994.0; 12857.9) 11940.5 (9510.9; 14148.6)
Week 12 8123.9 (6241.2; 12582.7) 8250.4 (6978.9; 12582.7) 7518.7 (5366.6; 11001.6)
sTNFRI Baseline 536.2 (288.7; 845.4) 551.4 (292.6; 860.6) 489.4 (284.7; 749.7)
Week 2 560.9 (347.2; 799.5) 647.5 (417.4; 803.7) 516.4 (302.3; 782.2)
Week 4 606.9 (379.0; 872.3) 646.0 (424.7; 742.0) 571.0 (379.0; 913.7)
Week 12 455.1 (347.2; 750.5) 532.9 (416.5; 753.8) 415.2 (319.4; 612.3)
sTNFRII Baseline 5441.7 (4425.5; 7722.1) 5441.7 (4285.5; 8470.5) 5582.4 (4539.0; 7230.2)
Week 2 5104.3 (3728.7; 6909.2) 5680.6 (4255.6; 7181.9) 4236.9 (3629.6; 6032.3)
Week 4 4757.1 (3718.4; 6621.7) 4307.4 (3531.6; 6486.4) 5766.0 (4121.2; 6922.4)
Week 12 4564.9 (3532.0; 6127.8) 4485.4 (3113.5; 6384.8) 4579.4 (3924.5; 5791.2)
IL-1RA Baseline 4.4 (0.0; 16.7) 10.2 (2.1; 18.8) 1.9 (0.0; 8.0)
Week 2 3.4 (0.0; 16.7) 11.3 (0.8; 25.8) 0.4 (0.0; 14.0)
Week 4 5.4 (0.0; 13.1) 5.7 (0.0; 11.5) 2.1 (0.0; 14.0)
Week 12 3.4 (0.0; 14.0) 5.1 (0.8; 15.1) 0.0 (0.0; 10.2)
Incident neuropathic symptoms developed within 12 weeks of starting cART.
The control group refers to the symptom-free nested control group paired for previously identified risk factors.
Time effect: Bold numbers denote values different from baseline, p < 0.05.
Group effect: Bold numbers denote values different between groups compared to baseline, p < 0.05.
Abbreviations: IQR interquartile range, sIL-1RI soluble IL-1 receptor I, sIL-1RII soluble IL-1 receptor II, sIL-2Rα soluble IL-2 receptor-α, sIL-4R soluble IL-4 receptor,
sIL-6R soluble IL-6 receptor, sTNFRI soluble TNF receptor I, sTNFRII soluble TNF receptor II, IL-1RA IL-l receptor antagonist.
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symptom status. Twelve of the 13 cytokines analysed in-
creased significantly within 4 weeks of cART initiation.
Cytokines such as IL-2, IL-12(p70) and IFNγ increased
by more than 200-times relative to pre-cART/baseline
concentrations before returning to baseline levels at 12
weeks. Although Padilla et al. also found increased levels
of IL-6 and hs-CRP at four weeks compared to baseline,
their cohort comprised a mixture of subjects either initi-
ating cART or re-starting [37].Although peak cytokine concentrations in this cohort
overall were lower than those reported in hospitalized
tuberculosis-associated IRIS patients [26,38], this study
population comprised ambulatory individuals attending
a community-based clinic. Parasitic- and non-parasitic in-
fections, as well as nutritional deficiencies could contrib-
ute to the degree of observed immune activation once the
HIV-induced functional inhibition is reversed by cART.
We speculate that the trend for lower cytokine peaks
in the symptomatic group may be the consequence of
Figure 2 Longitudinal evaluation of candidate pro-inflammatory/anti-inflammatory cytokine and cytokine/receptor ratios categorized
by incident neuropathic symptom status. Incident neuropathic symptoms developed within 12 weeks of starting cART. The control group
refers to the symptom-free nested control group paired for previously identified risk factors. *refers to within-group differences from baseline,
p < 0.05. # refers to between-group differences from baseline levels, p < 0.05. Horizontal bars indicate median values with interquartile ranges.
Baseline refers to pre-cART levels. Abbreviations: IL, interleukin; sIL, soluble interleukin; TNFα, tumour necrosis factor-α.
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cantly higher concentration of IL-1RA and soluble recep-
tors. For example, IL-1RA is released from hepatocytes
stimulated by circulating inflammatory mediators, and
also synthesized by locally activated monocytes [39,40].
Circulating IL-1RA during inflammatory stress may serve
to reduce the systemic responses to localized IL-1β
production. High levels of circulating IL-1RA have been
reported in many inflammatory settings including target-
organ autoimmune diseases such as rheumatoid arthritis
[29]. The pre-cART IL-1β/IL-1RA ratio in our control
group was similar to a previous and comparable cohort of
asymptomatic African women with reasonably preserved
CD4+ counts who were also cART-naive [41]. By com-
parison, the group developing neuropathic symptoms
showed a markedly altered IL-1β/IL-1RA ratio pre-
cART as a result of significantly higher IL-1RA levels.
We propose that higher plasma IL-1RA levels in those
who subsequently develop symptoms reflect the host’s
homeostatic mechanism aimed at downregulating pre-
existing inflammation. This may result in nerve dys-
function, possibly at the dorsal root ganglion (DRG)
when the blood-nerve barrier is impaired [41], causing
neuropathic symptoms after an additional insult such as
dNRTIs or the observed ‘cytokine burst’ after cART inti-
tiation. Although the factors driving the higher inflamma-
tory set-point in individuals predicted to develop early
incident neuropathic symptoms is unknown, careful atten-
tion to micro-nutritional status and concomitant drug
usage prior to starting cART may provide simple mea-
sures to reduce cellular oxidative stress known to augment
inflammation.
The DRG plays a pivotal role in the pathogenesis of
HIV-associated neuropathy which likely involves both in-
direct cytokine- and direct viral protein-mediated neuro-
toxicity [42]. Neuronal toxicity in the DRG is associated
with upregulated IL-1β and TNFα expression [42,43]. Sub-
clinical levels of inflammation such as local IL-1β produc-
tion, may prime proteinase-activated receptors (PAR)2 on
small DRG neurons and their afferent axons [44]. A “sec-
ond hit” such as the cART-associated subclinical “cytokine
burst” herein described, may facilitate further PAR2 activa-
tion with augmentation of nociceptive signaling via central
pathways [44,45].
Our study has several limitations. Plasma levels may
not reliably reflect perineural activation due to the local
action of cytokines at low concentrations. Therefore, sys-
temic cytokine levels might not accurately demonstrate
the extent of neural inflammation in individuals develop-
ing neuropathic symptoms. In addition, cytokines and
soluble receptor levels showed significant skewing and
variability. Fluctuation in cytokine levels may have af-
fected results although rank correlation analyses demon-
strated good within-individual stability and predictabilityfor the majority of cytokines. A random effects model
was used to limit the effect of variability and fluctuations
on the longitudinal analysis of cytokine levels. Although
the two individuals with detectable viral loads at 24 weeks
were excluded from the analysis, a degree of undetectable
viral replication may have confounded the interpretation
of the cytokine results. A further limitation is that CD4
counts were not available at the 12 week analysis point to
correlate with systemic cytokine levels. Also, our conclu-
sions are based on a small, matched sample, reducing our
statistical power to detect weaker associations. This preva-
lent cohort of HIV-infected individuals were “selected” at
the baseline visit for being free of neuropathic symp-
toms prior to cART exposure, which in itself may have
introduced selection bias. The symptomatic cases and
symptom-free controls were matched for factors known
to increase the risk for DSP, but there may be other fac-
tors, as yet unknown, that may also influence risk. Finally,
individuals with diabetes mellitus and current opportunis-
tic infections including tuberculosis (and anti-tuberculous
therapy) were excluded from our study and we therefore
do not know how these factors might have influenced our
results.Conclusion
In this case-control study of asymptomatic subjects starting
cART we show significant increases in cytokine levels
within the first 2-4 weeks after initiating therapy, a time
when susceptible individuals typically manifest pathological
IRIS. We found that individuals developing neuropathic
symptoms within 12 weeks of cART initiation have higher
baseline levels of IL-1RA even prior to starting cART. Our
conjecture is that this is evidence of a chronic host response
to inflammatory stimuli prior to cART in those individuals
who develop neuropathic symptoms. An additional “insult”
such as initiating cART with the observed cytokine burst
and higher ratios of pain-associated cytokines (TNFα/IL-4,
IL-6/IL-4 and IFNγ/IL-10), and concomitant increase in
soluble cytokine receptors (sIL-2Rα and sTNFRII), might
give rise to neuropathic symptoms via complex direct and
indirect signalling mechanisms.Additional file
Additional file 1: Supplementary Tables. Table S1– Cytokine
concentrations before cART initiation and longitudinally over the first 12
weeks categorized by incident neuropathic symptom status. Table S2 –
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concentrations, as well as the percentage of undetectable levels for each
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